Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Gordon Mills, MD is an obstetrician/gynecologist in Houston, Texas. He is currently licensed to practice medicine in Texas. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of AlbertaClass of 1977
Certifications & Licensure
TX State Medical License 1996 - 2018
Publications & Presentations
PubMed
- Automated machine learning profiling with MAP-HR for quantifying homologous recombination foci in patient samples.Tugba Y Ozmen, Matthew J Rames, Gabriel M Zangirolani, Furkan Ozmen, Kangjin Jeong
NAR Cancer. 2025-09-01 - The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.Qiuyang Xu, Yuanjia Wen, Taiyuan Huang, Huayi Li, Xingzhe Liu
Biomarker Research. 2025-08-20 - Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer.Xiaofei Jiao, Jiahao Liu, Yijie Wu, Qing Zhong, Li Zhu
Science Translational Medicine. 2025-08-13
Press Mentions
OHSU Scientists Develop Tool That Improves Tissue Cancer AnalysisJuly 16th, 2025- After Cancer Diagnoses, OHSU Patient Says Becoming a Mother Is ‘An Amazing Gift’April 16th, 2025
- Pangea Biomed Begins Pilot Collaboration with the OHSU Knight Cancer Institute to Improve Cancer Therapy PrecisionOctober 24th, 2024
- Join now to see all
Grant Support
- Systematic Characterization and Targeting of Neomorphic Drivers in CancerOREGON HEALTH & SCIENCE UNIVERSITY2023–2028
- The Cancer Proteome Atlas: an Integrated Bioinformatics Resource for Functional Cancer Proteomic DataUNIVERSITY OF TX MD ANDERSON CAN CTR2022–2027
- Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.OREGON HEALTH & SCIENCE UNIVERSITY2021–2026
- Biological Annotation Of TCGA DataNational Cancer Institute2012
- The Role Of Aberrant Splicing Of Evl1 In Ovarian Cancer PathophysiologyNational Cancer Institute2008–2012
- Role Of RAB25 And Its Effectors In Breast Cancer BioengenericsNational Cancer Institute2010–2011
- P4 - Pers. Therapy For High-Grade Ovarian Cancer: Targeting Pi3kness &BrcaneNational Cancer Institute2010–2011
- Modeling Response To P13K Targeted TherapiesNational Cancer Institute2010–2011
- Modeling Response To P13K Target TherapiesNational Cancer Institute2010–2011
- Predictors Of Resistance Dual Vegfr/Egfr Targeted Therapy Of Head And Neck CancerNational Cancer Institute2009–2011
- Integrative Pipeline For Analysis &Translational Application Of TCGA Data (GDAC)National Cancer Institute2009–2011
- Targeting The PI3K Pathway In Ovarian CancerNational Cancer Institute2008–2009
- P-3: Predictors Of Resistnace Todual Vegfr/Egfr Targeted Therapy Of H&N CancerNational Cancer Institute2008
- MMAC1/PTEN Tumor Suppressor And Breast CancerNational Cancer Institute1999–2003
- PI-3 Kinase Pathway In Ovarian CancerNational Cancer Institute2001–2002
- LPA In Initiation And Progression In Ovarian CancerNational Cancer Institute2001–2002
- Phosphatidylinositol Signaling In Ovarian Tumorigenesis, Prognosis &TherapyNational Cancer Institute1999–2002
- CD Signaling Through Emt/Itk Tyrosine KinaseNational Cancer Institute1997–2001
- Ovarian Cancer Activating Factor In Ovarian Cancer Initiation And ProgressionNational Cancer Institute1996–2000
- Putative Tumor Suppressor Ptp1c In Breast CancerNational Cancer Institute1996–1998
